Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Renub Research | PRODUCT CODE: 1702632

Cover Image

PUBLISHER: Renub Research | PRODUCT CODE: 1702632

Global Transcatheter Heart Valve Replacement Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033

PUBLISHED:
PAGES: 200 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF (Single User License)
USD 2990
PDF (5 User License + Excel)
USD 3490
PDF (Corporate License)
USD 3990

Add to Cart

Global Transcatheter Heart Valve Replacement Market Trends & Summary

Transcatheter Heart Valve Market is expected to reach US$ 19.69 billion in 2033 from US$ 7.10 billion in 2024, with a CAGR of 12.00% from 2025 to 2033. Ageing populations, a growth in cardiovascular disorders, improvements in minimally invasive technology, higher procedural success rates, and patient demand for safer treatments are the main factors driving the transcatheter heart valve replacement (THVR) market.

Transcatheter Heart Valve Replacement Market Global Report by Type (Transcatheter Aortic Valve Replacement, Transcatheter Mitral Valve Replacement, Transcatheter Pulmonary Valve Replacement), Material (Mechanical valves, Biological Valves), End-User (Hospitals, Ambulatory Surgical Centers, Others), Countries and Company Analysis 2025-2033.

Transcatheter Heart Valve Replacement Industry Overview

Patients with severe heart valve disease, especially aortic stenosis, can be treated with transcatheter heart valve replacement (THVR), a minimally invasive treatment. A catheter is guided to the heart during the surgery by being implanted into a blood artery, usually in the groin. The damaged valve is then replaced without open heart surgery by implanting a new, bioprosthetic valve. For high-risk patients or those unable to have standard surgery, THVR is the best option. The treatment is revolutionary in cardiovascular care since it shortens recovery times, decreases problems, and improves results when compared to standard valve replacement.

A number of factors are propelling the Transcatheter Heart Valve Replacement (THVR) market's expansion. Globally, the prevalence of cardiovascular illnesses, especially aortic stenosis, is rising as people age. High-risk patients who are unable to have open heart surgery can now choose THVR thanks to advancements in minimally invasive technologies and increased procedural success rates. Demand is also fueled by growing awareness of the advantages of THVR, such as shortened recovery times and fewer problems. Additionally, the market is developing as a result of healthcare professionals' increasing use of THVR procedures and the expansion of healthcare access. Market expansion is still being driven by ongoing research and product innovation.

Growth Drivers for the Transcatheter Heart Valve Replacement Market

Minimally Invasive Procedures

One of the main factors propelling the market for transcatheter heart valve replacement (THVR) is minimally invasive methods. These methods provide patients with a less traumatic and safer option than open heart surgery. With THVR, a new valve is inserted via a catheter, frequently through a little incision. This procedure speeds up hospital discharge, lowers the risk of complications, and greatly shortens recovery times. The use of THVR is growing as more patients choose less invasive procedures that have lower risks and a faster recovery. The market is growing as a result of this trend and developments in catheter-based technologies, which are increasing the use of THVR in the treatment of cardiovascular disorders.

Rising geriatric population

among the main factors propelling the market for transcatheter heart valve replacement (THVR) is the aging population. Age-related cardiovascular diseases, such as aortic stenosis, are becoming more common as the world's senior population grows.One in six individuals worldwide will be 60 years of age or older by 2030. At this point, there will be 1.4 billion people over the age of 60, up from 1 billion in 2020. The number of individuals in the world who are 60 years of age or older is expected to increase to 2.1 billion by 2050.Heart valve replacement treatments are in greater demand as a result of this demographic transition, especially for high-risk elderly patients who might not be good candidates for open heart surgery. Consequently, THVR turns into a necessary, non-intrusive choice that speeds up the market.

Ongoing Research & Development

The market for transcatheter heart valve replacement (THVR) is growing significantly due in large part to ongoing research and development (R&D). In addition to increasing the number of patients eligible for THVR, ongoing developments in valve design, materials, and delivery methods are also improving procedural outcomes. Innovations improve performance and lower problems, such as the creation of valves that are more patient-specific, flexible, and long-lasting. Additionally, R&D efforts are concentrated on improving imaging technologies to guarantee better clinical outcomes and more precise device installation. THVR keeps gaining traction as new technologies and procedural approaches develop, propelling market expansion and enhancing patient results.

In Nov 2024, at significant cardiology conferences, Meril Life Sciences showcased its Myval Octapro Transcatheter Heart Valve (THV), showcasing its technological breakthroughs in valve replacement. The novel valve is intended to enhance patient compatibility and procedure results. Meril's commitment to improving treatment for structural heart disease is demonstrated by its continuous research and innovation.

Challenges in the Transcatheter Heart Valve Replacement Market

High costs

One major obstacle in the market for transcatheter heart valve replacements (THVRs) is high pricing. The technique requires highly skilled medical personnel, costly gadgets, and specialized equipment, which raises the total cost of therapy. This may restrict patient access, particularly in areas with lower incomes or in healthcare systems with tighter finances. Even while THVR has advantages including a quicker recovery time, its expensive cost prevents it from being widely used, so finding affordable alternatives is crucial for future market expansion.

Existence of Substitute Products to Complicate the Market

Despite the benefits of minimally invasive transcatheter technology, traditional surgical valves are still used in many places, particularly in developing nations. Patients have a considerable need for the surgical valves. This is mostly due to the fact that surgical valves can last a lifetime and are more robust than transcatheter ones. One of the main things that can hurt the industry is the well-established existence of surgical valves.

Transcatheter Heart Valve Replacement Market Overview by Regions

Regional growth trends are evident in the market for transcatheter heart valve replacement (THVR). North America is in the lead because of its aging population, strong adoption rates, and sophisticated healthcare infrastructure. Demand is high in Europe, especially in nations like Germany and the UK. The Asia Pacific region is expanding quickly as a result of increased incidence of cardiovascular disease and better access to healthcare. Growing healthcare investments are fueling the market's slow expansion in Latin America and the Middle East.

United States Transcatheter Heart Valve Replacement Market

Due to an aging population and a high prevalence of cardiovascular illnesses, especially aortic stenosis, the United States Transcatheter Heart Valve Replacement (THVR) market is one of the largest segments in the world. The broad adoption of THVR is made possible by the nation's sophisticated healthcare infrastructure, easy access to state-of-the-art medical technology, and robust reimbursement support. Particularly for high-risk patients, THVR operations are becoming more and more popular over traditional surgery due to established clinical criteria and skilled specialists. The United States is positioned as a major player in the worldwide THVR market thanks to continued research, innovative valve design, and growing healthcare access.

In March 2024, for patients with symptomatic severe aortic stenosis, Medtronic announced that the FDA has authorized its Evolut FX+ transcatheter aortic valve replacement (TAVR) system. The diamond-shaped frame of this upgraded system provides improved coronary access while preserving the excellent valve performance for which the Evolut platform is renowned. Within two years, heart failure might result from severe aortic stenosis if treatment is not received.

Germany Transcatheter Heart Valve Replacement Market

Germany's sophisticated healthcare system, first-rate medical infrastructure, and aging population make it one of the continent's top markets for transcatheter heart valve replacement (THVR). The prevalence of heart valve disorders, such as aortic stenosis, raises the need for THVR operations. The extensive use of minimally invasive heart valve replacements is further aided by Germany's robust reimbursement regulations and highly qualified medical personnel. The market is also growing as a result of the nation's strong clinical research and development initiatives, with ongoing advancements in THVR technology improving patient results and increasing available treatments.

India Transcatheter Heart Valve Replacement Market

The market for transcatheter heart valve replacement (THVR) in India is expanding quickly as a result of an aging population, increased prevalence of cardiovascular illness, and better healthcare facilities. Adoption has been accelerated by advances in medical technology and growing knowledge of minimally invasive procedures. The growing middle class and government programs to increase access to healthcare are propelling market expansion, even if cost is still a barrier. The robust medical tourism industry in India is another factor driving up demand for THVR procedures.

Saudi Arabia Transcatheter Heart Valve Replacement Market

The market for transcatheter heart valve replacement (THVR) in Saudi Arabia is expanding quickly because to the country's aging population and rising prevalence of cardiovascular illnesses. The need for minimally invasive procedures like THVR is growing since cardiovascular diseases are one of the main causes of death. Government efforts to improve medical services and a strong healthcare infrastructure benefit the nation. The market is also growing as a result of the acceptance of these life-saving operations being fueled by improvements in THVR technology and growing patient awareness.

Transcatheter Heart Valve Replacement Market Segments

Type

1. Transcatheter Aortic Valve Replacement

2. Transcatheter Mitral Valve Replacement

3. Transcatheter Pulmonary Valve Replacement

Material

1. Mechanical valves

2. Biological Valves

End-User

1. Hospitals

2. Ambulatory Surgical Centers

3. Others

Countries

North America

1. United States

2. Canada

Europe

1. France

2. Germany

3. Italy

4. Spain

5. United Kingdom

6. Belgium

7. Netherlands

8. Turkey

Asia Pacific

1. China

2. Japan

3. India

4. South Korea

5. Thailand

6. Malaysia

7. Indonesia

8. Australia

9. New Zealand

Latin America

1. Brazil

2. Mexico

3. Argentina

Middle East & Africa

1. Saudi Arabia

2. UAE

3. South Africa

Rest of the World

All the Key players have been covered from 5 Viewpoints:

1. Overview

2. Key Persons

3. Product Portfolio

4. Recent Development & Strategies

5. Sales Analysis

Key Players Analysis

1. Edwards Lifesciences

2. Abbott Laboratories

3. Medtronic Plc

4. LIVANOVA PLC

5. Boston Scientific Corporation

6. Artivion, Inc.

7. MicroPort Scientific Corporation

8. Venus Medtech (Hangzhou) Inc.

Table of Contents

1. Introduction

2. Research & Methodology

3. Executive Summary

4. Market Dynamics

  • 4.1 Growth Drivers
  • 4.2 Challenges

5. Global Transcatheter Heart Valve Replacement Market

6. Market Share Analysis

  • 6.1 by Type
  • 6.2 by Material
  • 6.3 by End User
  • 6.4 by Countries

7. Type

  • 7.1 Transcatheter Aortic Valve Replacement
  • 7.2 Transcatheter Mitral Valve Replacement
  • 7.3 Transcatheter Pulmonary Valve Replacement

8. Material

  • 8.1 Mechanical valves
  • 8.2 Biological Valves

9. End-User

  • 9.1 Hospitals
  • 9.2 Ambulatory Surgical Centers
  • 9.3 Others

10. Countries

  • 10.1 North America
    • 10.1.1 United States
    • 10.1.2 Canada
  • 10.2 Europe
    • 10.2.1 France
    • 10.2.2 Germany
    • 10.2.3 Italy
    • 10.2.4 Spain
    • 10.2.5 United Kingdom
    • 10.2.6 Belgium
    • 10.2.7 Netherlands
    • 10.2.8 Turkey
  • 10.3 Asia Pacific
    • 10.3.1 China
    • 10.3.2 Japan
    • 10.3.3 India
    • 10.3.4 South Korea
    • 10.3.5 Thailand
    • 10.3.6 Malaysia
    • 10.3.7 Indonesia
    • 10.3.8 Australia
    • 10.3.9 New Zealand
  • 10.4 Latin America
    • 10.4.1 Brazil
    • 10.4.2 Mexico
    • 10.4.3 Argentina
  • 10.5 Middle East & Africa
    • 10.5.1 Saudi Arabia
    • 10.5.2 UAE
    • 10.5.3 South Africa
  • 10.6 Rest of the world

11. Porter's Five Forces Analysis

  • 11.1 Bargaining Power of Buyers
  • 11.2 Bargaining Power of Suppliers
  • 11.3 Degree of Rivalry
  • 11.4 Threat of New Entrants
  • 11.5 Threat of Substitutes

12. SWOT Analysis

  • 12.1 Strength
  • 12.2 Weakness
  • 12.3 Opportunity
  • 12.4 Threat

13. Key Players Analysis

  • 13.1 Edwards Lifesciences
    • 13.1.1 Overview
    • 13.1.2 Key Persons
    • 13.1.3 Product Portfolio
    • 13.1.4 Recent Development & Strategies
    • 13.1.5 Sales Analysis
  • 13.2 Abbott Laboratories
    • 13.2.1 Overview
    • 13.2.2 Key Persons
    • 13.2.3 Product Portfolio
    • 13.2.4 Recent Development & Strategies
    • 13.2.5 Sales Analysis
  • 13.3 Medtronic Plc
    • 13.3.1 Overview
    • 13.3.2 Key Persons
    • 13.3.3 Product Portfolio
    • 13.3.4 Recent Development & Strategies
    • 13.3.5 Sales Analysis
  • 13.4 LIVANOVA PLC
    • 13.4.1 Overview
    • 13.4.2 Key Persons
    • 13.4.3 Product Portfolio
    • 13.4.4 Recent Development & Strategies
    • 13.4.5 Sales Analysis
  • 13.5 Boston Scientific Corporation
    • 13.5.1 Overview
    • 13.5.2 Key Persons
    • 13.5.3 Product Portfolio
    • 13.5.4 Recent Development & Strategies
    • 13.5.5 Sales Analysis
  • 13.6 Artivion, Inc.
    • 13.6.1 Overview
    • 13.6.2 Key Persons
    • 13.6.3 Product Portfolio
    • 13.6.4 Recent Development & Strategies
    • 13.6.5 Sales Analysis
  • 13.7 MicroPort Scientific Corporation
    • 13.7.1 Overview
    • 13.7.2 Key Persons
    • 13.7.3 Product Portfolio
    • 13.7.4 Recent Development & Strategies
    • 13.7.5 Sales Analysis
  • 13.8 Venus Medtech (Hangzhou) Inc.
    • 13.8.1 Overview
    • 13.8.2 Key Persons
    • 13.8.3 Product Portfolio
    • 13.8.4 Recent Development & Strategies
    • 13.8.5 Sales Analysis
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!